61. Paz-Ares L, Perol M, Ciuleanu T -E, Kowalyszyn RD, Reck M, Lewanski CR, et al. Explor atory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: a randomized Phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second -line treatment of stage IV non -small -cell lung cancer (NSCLC). J clin Onco l 2015;33 (suppl.